Silexion Therapeutics Corp reported second-quarter and six-month financial results ending June 30, 2026. The company incurred a net loss of $3.6 million for the quarter and $6.3 million for the six-month period, driven by increased research and development expenses related to its Phase 2/3 clinical trial preparations. R&D expenses rose 120% year-over-year to approximately $2.2 million in Q2. The company closed a public offering on August 13, 2026, raising gross proceeds of approximately $2.5 million and net proceeds of $2.1 million. Silexion also announced the successful initiation of its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center in July 2026, following regulatory approvals in Israel and Germany. The company states it has restored compliance with Nasdaq’s shareholders’ equity listing requirement. Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven cancers.

Silexion Therapeutics Corp published an updated corporate presentation on August 10, 2026, detailing the clinical development timeline for its lead product candidate, SIL 204. The company announced that a Phase 2/3 clinical program investigating the dual-delivery strategy of SIL 204 for locally advanced pancreatic cancer was initiated in July 2026 following regulatory approvals in Israel and Germany. Early human data from this trial is expected in Q4 2026, with expansion phases planned for 2027 and confirmatory trials starting in 2030. Silexion Therapeutics Corp operates in the biotechnology industry, developing RNA silencing therapeutics for oncology.

Silexion Therapeutics Corp reported that Professor Amnon Peled resigned from its Board of Directors and all committees, including the audit committee, effective August 1, 2026. The resignation was for personal reasons and not due to disagreements regarding operations or policies. To fill the resulting vacancy, the Board appointed existing independent director Avner Lushi to the audit committee on the same date. Mr. Lushi serves as Managing Partner and CEO of the Guangzhou Sino-Israel Bio-industry Investment Fund and brings extensive board experience in life sciences investments. This appointment restored full compliance with Nasdaq Listing Rule 5605(c)(2)(A) by ensuring the audit committee consists of three independent members, eliminating reliance on any cure period. The company operates in the biotechnology sector.

Silexion Therapeutics announced the successful initiation of its Phase 2/3 clinical trial for SIL204, a small interfering RNA therapy targeting KRAS-driven locally advanced pancreatic cancer. The first site activated is Tel Aviv Sourasky Medical Center in Israel, which has cleared patient screening with dosing anticipated in coming weeks. This milestone follows regulatory approvals from the Israeli Ministry of Health and Germany’s BfArM, marking the transition from preparation to active clinical execution. Additional sites in Israel and Germany are expected to join soon. Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven cancers.